Pharmaron Beijing Co., Ltd. (HKG:3759)

Market Cap	61.73B
Revenue (ttm)	14.80B
Net Income (ttm)	1.65B
Shares Out	n/a
EPS (ttm)	0.94
PE Ratio	37.34
Forward PE	26.79
Dividend	0.22 (0.88%)
Ex-Dividend Date	Jul 4, 2025

Volume	9,227,994
Average Volume	6,614,808
Open	25.18
Previous Close	25.42
Day's Range	24.74 - 26.64
52-Week Range	10.46 - 30.12
Beta	0.98
RSI	54.36
Earnings Date	Oct 28, 2025

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotide...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 21,370
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3759

Financial Performance

In 2024, Pharmaron Beijing's revenue was 12.28 billion, an increase of 6.39% compared to the previous year's 11.54 billion. Earnings were 1.79 billion, an increase of 12.01%.

Financial numbers in CNY